Literature DB >> 31990287

Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversed by blood transfusion.

Shin-Young Park1, Alessandro Matte2, Yookyung Jung3,4, Jina Ryu1, Wilson Babu Anand2, Eun-Young Han1, Min Liu1, Carmine Carbone2, Davide Melisi2, Takashi Nagasawa5, Joseph J Locascio6, Charles P Lin4, Leslie E Silberstein1,7, Lucia De Franceschi2.   

Abstract

Sickle cell disease (SCD) is a monogenic red blood cell (RBC) disorder with high morbidity and mortality. Here, we report, for the first time, the impact of SCD on the bone marrow (BM) vascular niche, which is critical for hematopoiesis. In SCD mice, we find a disorganized and structurally abnormal BM vascular network of increased numbers of highly tortuous arterioles occupying the majority of the BM cavity, as well as fragmented sinusoidal vessels filled with aggregates of erythroid and myeloid cells. By in vivo imaging, sickle and control RBCs have significantly slow intravascular flow speeds in sickle cell BM but not in control BM. In sickle cell BM, we find increased reactive oxygen species production in expanded erythroblast populations and elevated levels of HIF-1α. The SCD BM exudate exhibits increased levels of proangiogenic growth factors and soluble vascular cell adhesion molecule-1. Transplantation of SCD mouse BM cells into wild-type mice recapitulates the SCD vascular phenotype. Our data provide a model of SCD BM, in which slow RBC flow and vaso-occlusions further diminish local oxygen availability in the physiologic hypoxic BM cavity. These events trigger a milieu that is conducive to aberrant vessel growth. The distorted neovascular network is completely reversed by a 6-week blood transfusion regimen targeting hemoglobin S to <30%, highlighting the plasticity of the vascular niche. A better insight into the BM microenvironments in SCD might provide opportunities to optimize approaches toward efficient and long-term hematopoietic engraftment in the context of curative therapies.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2020        PMID: 31990287      PMCID: PMC7273832          DOI: 10.1182/blood.2019002227

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  80 in total

1.  Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease.

Authors:  Christoph J Griessenauer; Jeffrey D Lebensburger; Michelle H Chua; Winfield S Fisher; Lee Hilliard; Christina J Bemrich-Stolz; Thomas H Howard; James M Johnston
Journal:  J Neurosurg Pediatr       Date:  2015-04-03       Impact factor: 2.375

Review 2.  Pericytes: developmental, physiological, and pathological perspectives, problems, and promises.

Authors:  Annika Armulik; Guillem Genové; Christer Betsholtz
Journal:  Dev Cell       Date:  2011-08-16       Impact factor: 12.270

3.  Serum levels of angiogenic factors indicate a pro-angiogenic state in adults with sickle cell disease.

Authors:  Ashley J Duits; Tati Rodriguez; John-John B Schnog
Journal:  Br J Haematol       Date:  2006-07       Impact factor: 6.998

Review 4.  VEGF and angiopoietin signaling in tumor angiogenesis and metastasis.

Authors:  Pipsa Saharinen; Lauri Eklund; Kristina Pulkki; Petri Bono; Kari Alitalo
Journal:  Trends Mol Med       Date:  2011-04-12       Impact factor: 11.951

Review 5.  Sickle cell disease.

Authors:  Gregory J Kato; Frédéric B Piel; Clarice D Reid; Marilyn H Gaston; Kwaku Ohene-Frempong; Lakshmanan Krishnamurti; Wally R Smith; Julie A Panepinto; David J Weatherall; Fernando F Costa; Elliott P Vichinsky
Journal:  Nat Rev Dis Primers       Date:  2018-03-15       Impact factor: 52.329

Review 6.  Sickle cell anemia.

Authors:  G J Lonergan; D B Cline; S L Abbondanzo
Journal:  Radiographics       Date:  2001 Jul-Aug       Impact factor: 5.333

7.  Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches.

Authors:  Lei Ding; Sean J Morrison
Journal:  Nature       Date:  2013-02-24       Impact factor: 49.962

8.  Osteoblastic cells regulate the haematopoietic stem cell niche.

Authors:  L M Calvi; G B Adams; K W Weibrecht; J M Weber; D P Olson; M C Knight; R P Martin; E Schipani; P Divieti; F R Bringhurst; L A Milner; H M Kronenberg; D T Scadden
Journal:  Nature       Date:  2003-10-23       Impact factor: 49.962

9.  Spontaneous circulation of myeloid-lymphoid-initiating cells and SCID-repopulating cells in sickle cell crisis.

Authors:  Christopher E D Lamming; Lance Augustin; Mark Blackstad; Troy C Lund; Robert P Hebbel; Catherine M Verfaillie
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

Review 10.  Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies.

Authors:  Agnieszka Zimna; Maciej Kurpisz
Journal:  Biomed Res Int       Date:  2015-06-04       Impact factor: 3.411

View more
  21 in total

Review 1.  Gene therapy using haematopoietic stem and progenitor cells.

Authors:  Giuliana Ferrari; Adrian J Thrasher; Alessandro Aiuti
Journal:  Nat Rev Genet       Date:  2020-12-10       Impact factor: 53.242

Review 2.  Editing outside the body: Ex vivo gene-modification for β-hemoglobinopathy cellular therapy.

Authors:  Tolulope O Rosanwo; Daniel E Bauer
Journal:  Mol Ther       Date:  2021-10-08       Impact factor: 11.454

3.  Advances in 3D Vascularized Tumor-on-a-Chip Technology.

Authors:  Sangmin Jung; Hyeonsu Jo; Sujin Hyung; Noo Li Jeon
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

Review 4.  Targeting the Hematopoietic Stem Cell Niche in β-Thalassemia and Sickle Cell Disease.

Authors:  Annamaria Aprile; Silvia Sighinolfi; Laura Raggi; Giuliana Ferrari
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-11

5.  Revisiting anemia in sickle cell disease and finding the balance with therapeutic approaches.

Authors:  Julia Zhe Xu; Swee Lay Thein
Journal:  Blood       Date:  2022-05-19       Impact factor: 25.476

Review 6.  Genetic therapies for the first molecular disease.

Authors:  Phillip A Doerfler; Akshay Sharma; Jerlym S Porter; Yan Zheng; John F Tisdale; Mitchell J Weiss
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

7.  Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development.

Authors:  Paula Cannon; Aravind Asokan; Agnieszka Czechowicz; Paula Hammond; Donald B Kohn; Andre Lieber; Punam Malik; Peter Marks; Matthew Porteus; Els Verhoeyen; Drew Weissman; Irving Weissman; Hans-Peter Kiem
Journal:  Hum Gene Ther       Date:  2021-01       Impact factor: 5.695

Review 8.  Transfusion and Cellular Therapy in Pediatric Sickle Cell Disease.

Authors:  Yan Zheng; Stella T Chou
Journal:  Clin Lab Med       Date:  2020-12-24       Impact factor: 1.935

Review 9.  Update on Clinical Ex Vivo Hematopoietic Stem Cell Gene Therapy for Inherited Monogenic Diseases.

Authors:  Francesca Tucci; Samantha Scaramuzza; Alessandro Aiuti; Alessandra Mortellaro
Journal:  Mol Ther       Date:  2020-11-20       Impact factor: 11.454

10.  Murine bone marrow mesenchymal stromal cells have reduced hematopoietic maintenance ability in sickle cell disease.

Authors:  Alice Tang; Ana Nicolle Strat; Mahmudur Rahman; Helen Zhang; Weili Bao; Yunfeng Liu; David Shi; Xiuli An; Deepa Manwani; Patricia Shi; Karina Yazdanbakhsh; Avital Mendelson
Journal:  Blood       Date:  2021-12-16       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.